Chronic wounds in diabetic patients are difficult to treat due to persistent inflammation, impaired angiogenesis, and oxidative stress. To address this, we developed injectable DNA-guided siliceous microgels inspired by marine biosilica and refined through AI-based modeling for tunable particle sizes ensuring syringe compatibility. These microgels showed robust structural integrity, biomimetic features, and colloidal stability. Silica-infused formulations exhibited excellent biocompatibility, exudate absorption, ROS scavenging, and hemostatic performance. In vitro, they promoted M2 macrophage polarization, fibroblast/endothelial cell proliferation, and oxidative protection. In vivo, they accelerated wound closure, re-epithelialization, collagen deposition, and angiogenesis while reducing inflammation. This platform supports all wound healing phases, offering a multifunctional strategy for chronic wound therapy.